April 13, 2012 | Vol. 4 No. 15
The increased use of automated control systems for cut labeling can reduce the risk of human error during the packaging process, the FDA says in a regulatory tweak that allows drugmakers greater flexibility in meeting manufacturing requirements.
A reported snag in settlement talks between federal prosecutors and Johnson & Johnson (J&J) over off-label marketing could signal the government wants to standardize its approach to prosecuting such allegations.
The FDA’s consent decree for Ranbaxy requires third-party audits of four facilities and it can be expanded to other plants if future inspections reveal compliance or data integrity issues, making it “unprecedented in scope,” the Department of Justice (DOJ) says.
The FDA granted approval to Affymax and Takeda’s once-monthly anemia treatment Omontys, but has loaded the companies with postmarketing requirements, including two safety studies and a risk evaluation and mitigation strategy (REMS).
A seven-observation Form 483 handed to Hi-Tech Phamacal cites deficient dust control at the contract manufacturer’s Amityville, N.Y., facility.
German devicemaker I.E.M. was hit with a warning letter after FDA investigators found shortcomings with medical device report (MDR) procedures and an array of quality “nonconformities” during a recent inspection of the company’s Stolberg, Germany, facility.
The FDA has halted approval of new trials and enrollment in ongoing studies reviewed by the investigational review board (IRB) BioMed after two negative assessments of the board’s work.
The FDA has escalated a long-simmering dispute with Israeli-owned software developer NeuroTrax about the proper classification of its MindStreams cognitive health assessment tool, telling the company in a warning letter it must seek Class III status or halt marketing the product.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.